<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00421473</url>
  </required_header>
  <id_info>
    <org_study_id>UMCN-AKF 06.02</org_study_id>
    <nct_id>NCT00421473</nct_id>
  </id_info>
  <brief_title>Drug Interaction Study Between Atovaquone and Antiretroviral Agents in HIV-1 Infected Patients</brief_title>
  <official_title>Drug Interactions Between ATOvaquone Used in MAlaria Prophylaxis and Antiretroviral Agents in HIV-1 Infected Patients (ATOMA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <brief_summary>
    <textblock>
      MalaroneÂ® (atovaquone/proguanil) is frequently used in malaria prophylaxis. Unfortunately,&#xD;
      there are indications that certain anti-HIV agents may decrease atovaquone plasma levels by&#xD;
      induction of atovaquone metabolism.&#xD;
&#xD;
      For travelling HIV patients, the clinical consequences of these possible drug drug&#xD;
      interactions are serious, since a diminished exposure to the anti-malarial drug will result&#xD;
      in suboptimal prophylaxis of malaria and potential development of drug resistant strains of&#xD;
      Plasmodium falciparum.&#xD;
&#xD;
      The purpose of this study is to find out if HIV patients using HAART regimes with either&#xD;
      lopinavir/ritonavir, atazanavir/ritonavir or efavirenz have lower atovaquone plasma levels&#xD;
      than healthy volunteers after a single dose of atovaquone/proguanil.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic blood samples will be taken just before dosing Malarone, and 12 samples in the time between 0,5 hour and 168 hours after dosing.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood will be taken for genotyping of CYP2C19 at study day 1.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-1 RNA and CD4 determination will be done (HIV patients only) at inclusion screening</measure>
  </secondary_outcome>
  <enrollment type="Actual">79</enrollment>
  <condition>HIV Infections</condition>
  <condition>Malaria</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atovaquone / Proguanil</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For healthy volunteers&#xD;
&#xD;
          -  18 - 65 years&#xD;
&#xD;
          -  smoking habits &lt; 10 cigarettes, 2 cigars or 2 pipes&#xD;
&#xD;
          -  BMI between 18 and 30 kg/m2&#xD;
&#xD;
          -  able and willing to sign informed consent form&#xD;
&#xD;
          -  subject is in a good age-appropriate health condition&#xD;
&#xD;
          -  subject has a normal blood pressure and pulse rate&#xD;
&#xD;
        For HIV patients&#xD;
&#xD;
          -  HIV-infected as documented by positive HIV antibody test and confirmed by Western&#xD;
             Blot.&#xD;
&#xD;
          -  CD4+ &gt; 200 * 10E6 per Liter.&#xD;
&#xD;
          -  18 - 65 years&#xD;
&#xD;
          -  BMI between 18 and 30 kg/m2&#xD;
&#xD;
          -  able and willing to sign informed consent form&#xD;
&#xD;
          -  use of lopinavir/ritonavir, atazanavir/ritonavir or efavirenz for at least 1 month in&#xD;
             a dose of 400/100mg bid, 300/100 mg QD, or 600 mg QD respectively&#xD;
&#xD;
        Exclusion Criteria healthy volunteers:&#xD;
&#xD;
          -  History of sensitivity/idiosyncrasy to atovaquone/proguanil or chemically related&#xD;
             compounds or excipients.&#xD;
&#xD;
          -  Positive HIV test.&#xD;
&#xD;
          -  Positive HbsAg test (hepatitis B) or positive hepatitis C test.&#xD;
&#xD;
          -  Therapy with any drug (for two weeks preceding dosing), except for paracetamol.&#xD;
&#xD;
          -  Creatinine clearance &lt; 60 mL/min (calculated from serum creatinine)&#xD;
&#xD;
          -  Current diarrhoea.&#xD;
&#xD;
          -  Relevant history or current condition that might interfere with drug absorption,&#xD;
             distribution, metabolism or excretion.&#xD;
&#xD;
          -  History of or current abuse of drugs, alcohol or solvents.&#xD;
&#xD;
          -  Inability to understand the nature and extent of the trial and the procedures&#xD;
             required.&#xD;
&#xD;
          -  Participation in a drug trial within 60 days prior to the first dose.&#xD;
&#xD;
          -  Donation of blood within 60 days prior to the first dose.&#xD;
&#xD;
          -  Pregnant female (as confirmed by an HCG test performed less than 3 weeks before the&#xD;
             first dose) or breast-feeding female.&#xD;
&#xD;
          -  Abnormal serum transaminases, determined as levels being &gt; 3 times up-per limit of&#xD;
             normal&#xD;
&#xD;
          -  Febrile illness within 3 days before the first dose&#xD;
&#xD;
        Exclusion criteria HIV patients:&#xD;
&#xD;
          -  History of sensitivity/idiosyncrasy to atovaquone/proguanil or chemically related&#xD;
             compounds or excipients.&#xD;
&#xD;
          -  Suspicion of non-adherence to the HIV medication.&#xD;
&#xD;
          -  Current diarrhoea.&#xD;
&#xD;
          -  Relevant history or current condition that might interfere with drug absorption,&#xD;
             distribution, metabolism or excretion.&#xD;
&#xD;
          -  Inability to understand the nature and extent of the trial and the procedures&#xD;
             required.&#xD;
&#xD;
          -  Pregnant female (as confirmed by an HCG test performed less than 3 weeks before the&#xD;
             first dose) or breast-feeding female.&#xD;
&#xD;
          -  Abnormal serum transaminases determined as levels being &gt; 3 times upper limit of&#xD;
             normal&#xD;
&#xD;
          -  Creatinine clearance &lt; 60 mL/min (calculated from serum creatinine).&#xD;
&#xD;
          -  Any change in antiretroviral medication within 1 month immediately pre- ceding the&#xD;
             dose of atovaquone/proguanil.&#xD;
&#xD;
          -  Concomitant use of medications that interfere with atovaquone or proguanil&#xD;
             pharmacokinetics: anti-coagulants, aurothioglucose, chloroquine, cimetidine,&#xD;
             fluoxetine, fluvoxamine, metoclopramide, omeprazole, magnesiumtrisilicate, rifabutin,&#xD;
             rifampin, tetracycline, typhoid vaccine, topiramate.&#xD;
&#xD;
          -  Use of a HAART regime containing both lopinavir/ritonavir and another protease&#xD;
             inhibitor or a NNRTI.&#xD;
&#xD;
          -  Use of a HAART regime containing both atazanavir/ritonavir and another protease&#xD;
             inhibitor or a NNRTI.&#xD;
&#xD;
          -  Use of a HAART regime containing both efavirenz and one or more protease inhibitors or&#xD;
             nevirapine.&#xD;
&#xD;
          -  Active hepatobiliary or hepatic disease&#xD;
&#xD;
          -  Alcohol abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>D.M. Burger, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University Medical Centre Nijmegen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Elisabeth hospital</name>
      <address>
        <city>Tilburg</city>
        <state>Brabant</state>
        <zip>5022 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alysis Zorggroep loc. Rijnstate</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <zip>6800 TA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Centre Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <state>Zuid Holland</state>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid Holland</state>
        <zip>3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <results_reference>
    <citation>van Luin M, Van der Ende ME, Richter C, Visser M, Faraj D, Van der Ven A, Gelinck L, Kroon F, Wit FW, Van Schaik RH, Kuks PF, Burger DM. Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir. AIDS. 2010 May 15;24(8):1223-6. doi: 10.1097/QAD.0b013e3283389129.</citation>
    <PMID>20299957</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 11, 2007</study_first_submitted>
  <study_first_submitted_qc>January 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2007</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <keyword>HIV</keyword>
  <keyword>Malaria prophylaxis</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atovaquone</mesh_term>
    <mesh_term>Proguanil</mesh_term>
    <mesh_term>Atovaquone, proguanil drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

